open access

Ahead of print
Original articles
Published online: 2017-07-07
Submitted: 2017-02-27
Accepted: 2017-06-01
Get Citation

Severe mitral regurgitation is associated with increased copeptin levels in heart failure with reduced ejection fraction

Alev Kılıcgedık, Elıf Eroglu, Gokhan Kahvecı, Khaganı Isgandarov, Emrah Acar, Semi Ozturk, Regayip Zehir, Seyhmus Kulahcıoglu, Cuneyt Toprak, Ali Yaman, Ibrahım Akın Izgı, Cevat Kirma
DOI: 10.5603/KP.a2017.0140

open access

Ahead of print
Original articles
Published online: 2017-07-07
Submitted: 2017-02-27
Accepted: 2017-06-01

Abstract

Background and aim: The objective of this study was to assess the potential role of mitral regurgitation (MR) in the release of copeptin in HF patients with reduced ejection fraction (HFREF).

Methods: The study included 63 patients of whom 33 had functional mild MR (Group 1)  and 30 had functional severe MR (Group 2).The functional classes of the groups were both  NYHA Class III. Blood samples for the determination of plasma copeptin and B-type natriuretic peptide (BNP) levels were obtained at the same day with the echocardiographic examination. Standard echocardiographic studies were performed.

Results: Copeptin and BNP levels showed a substantial agreement in whole study group (Kappa level: 0.607, p < 0.0001). Also, copeptin and BNP showed a strong correlation and were both increased and significantly higher in Group 2 than Group 1 (p< 0.001 and p< 0.05, respectively ). Left ventricular global longitudinal strain  and LVEF values were similar in both groups. The study population were divided into two subgroups on the basis of copeptin median level (6.4 ng/mL), and the prevalence of severe MR were significantly higher in the above median copeptin subgroup. A linear regression analysis showed that the presence of severe MR was the only independent predictor of high circulating plasma copeptin level ( OR:7.5 ( 95% CI 2.8-12.1), p = 0.002).

Conclusions: Severe MR is an independent predictor of elevated plasma copeptin level in HFREF irrespective of systolic function.

Abstract

Background and aim: The objective of this study was to assess the potential role of mitral regurgitation (MR) in the release of copeptin in HF patients with reduced ejection fraction (HFREF).

Methods: The study included 63 patients of whom 33 had functional mild MR (Group 1)  and 30 had functional severe MR (Group 2).The functional classes of the groups were both  NYHA Class III. Blood samples for the determination of plasma copeptin and B-type natriuretic peptide (BNP) levels were obtained at the same day with the echocardiographic examination. Standard echocardiographic studies were performed.

Results: Copeptin and BNP levels showed a substantial agreement in whole study group (Kappa level: 0.607, p < 0.0001). Also, copeptin and BNP showed a strong correlation and were both increased and significantly higher in Group 2 than Group 1 (p< 0.001 and p< 0.05, respectively ). Left ventricular global longitudinal strain  and LVEF values were similar in both groups. The study population were divided into two subgroups on the basis of copeptin median level (6.4 ng/mL), and the prevalence of severe MR were significantly higher in the above median copeptin subgroup. A linear regression analysis showed that the presence of severe MR was the only independent predictor of high circulating plasma copeptin level ( OR:7.5 ( 95% CI 2.8-12.1), p = 0.002).

Conclusions: Severe MR is an independent predictor of elevated plasma copeptin level in HFREF irrespective of systolic function.

Get Citation

Keywords

copeptin, heart failure, functional mitral regurgitation

About this article
Title

Severe mitral regurgitation is associated with increased copeptin levels in heart failure with reduced ejection fraction

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Ahead of print

Published online

2017-07-07

DOI

10.5603/KP.a2017.0140

Keywords

copeptin
heart failure
functional mitral regurgitation

Authors

Alev Kılıcgedık
Elıf Eroglu
Gokhan Kahvecı
Khaganı Isgandarov
Emrah Acar
Semi Ozturk
Regayip Zehir
Seyhmus Kulahcıoglu
Cuneyt Toprak
Ali Yaman
Ibrahım Akın Izgı
Cevat Kirma

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl